Annovis Bio, Inc.

NYSE:ANVS

Biotechnology

Healthcare
$1.21 +0.00%

+$0.00 today

Market cap
$51.64M
Beta
1.24
P/E (TTM)
-1.1
EPS (TTM)
-$1.47
52W Low $1.54High $5.50

Volume 1.35M

Average 1.08M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$25.62B

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$34.60B

FY 2025 · Annual

+29.6% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(14.49M)(25.33M)(56.2M)(24.59B)(28.85B)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation4.7M9.15M4.63M3.84B1.8B
Change in Working Capital657.35K(1.14M)(228.6K)681.71K1.58M
Accounts Receivables00000
Inventory00000
Accounts Payables346.22K3.27M(2.67M)1.01M284.54K
Other Working Capital311.13K(4.41M)2.44M(331.43K)1.29M
Other Non-Cash Items0011.84M(1.14B)1.44B
Operating Cash Flow(9.13M)(17.31M)(39.97M)(21.89B)(25.62B)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued46.65M4.61K16.89M18.67M34.6M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities95.1K0458.39K26.67B34.57B
Financing Cash Flow46.74M4.61K17.34M26.69B34.6B
Effect of Forex Changes00000
Net Change in Cash37.61M(17.31M)(22.62M)4.8B8.98B
Free Cash Flow(9.13M)(17.31M)(39.97M)(21.89B)(25.62B)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$28.9B
+ D&A$0
+ Stock-Based Comp$1.8B
+ Deferred Tax$0
+ Working Capital$1.6M
+ Other Non-Cash$1.4B
= Operating Cash Flow-$25.6B
- Capex$0
= Free Cash Flow-$25.6B

Analysis

FY2025 free cash flow is -$25.6B. FCF conversion is 88.8% of net income. Operating cash flow was -$25.6B, with capex of $0. The largest bridge item is Stock-Based Comp at $1.8B.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
DEF 14ADEF 14A filingSep 11, 2026
PRE 14APRE 14A filingAug 25, 2026
10-QQuarterly reportAug 14, 2026
SC 13GSC 13G filingAug 14, 2026
8-KCurrent reportAug 14, 2026

Does ANVS generate free cash flow?

Annovis Bio, Inc. (ANVS) generated -$25.62B of free cash flow in fiscal 2025.

How much operating cash flow does ANVS produce?

Operating cash flow was -$25.62B, before capital expenditures of $0.00.